0
Cardiovascular Disease |

Cardiovascular Disease Profile of Patients With Chronic Obstructive Pulmonary Disease: Results From the National Health and Nutrition Examination Survey (NHANES)

Shikhar Agarwal*, MD; Haala Rokadia, MD; Todd Senn, MD
Author and Funding Information

Cleveland Clinic, Cleveland, OH


Chest. 2012;142(4_MeetingAbstracts):86A. doi:10.1378/chest.1387223
Text Size: A A A
Published online

Abstract

SESSION TYPE: Arrhythmia and Coronary Artery Disease

PRESENTED ON: Monday, October 22, 2012 at 11:15 AM - 12:30 PM

PURPOSE: Atherosclerotic cardiovascular and cerebrovascular disease(CCVD) is an important comorbidity associated with chronic obstructive pulmonary disease(COPD). We compared the prevalence of CCVD between COPD and non-COPD subjects. Additionally, among subjects without pre-existent CCVD, we compared the short-term(10-year) and lifetime risk of development of CCVD in the two study groups.

METHODS: Pooled data from the NHANES-2007-2010 were utilized. CCVD was defined as self-reported history of stroke, angina/heart attack, coronary artery disease or congestive heart failure. COPD was defined as either a self-reported history of emphysema or FEV1/FVC ratio<70% on serial spirometric assessment before and after administration of a bronchodilator. Based on predicted risk per standard Framingham criteria, subjects without pre-existing CCVD were classified into three groups: high short-term risk, low short-term/high lifetime risk, low short-term/low lifetime risk for development of CCVD.

RESULTS: The prevalence(SE) of CCVD was estimated as 20.0(2.1)% and 7.4(0.5)% in COPD and non-COPD groups(p<0.001). Among subjects with CCVD, the prevalence of active/former smokers was significantly higher in the COPD population(92.4%) as compared to controls(58.1%, p<0.001). Using multivariate analysis, COPD was demonstrated to be an independent risk factor for prevalent CCVD [OR(95%CI):1.7(1.1-2.6)], after adjustment for demographic and clinical characteristics including smoking. Among subjects without CCVD, there were significant differences in predicted cardiovascular risk between the two groups. In the non-COPD category, prevalence of subjects with high short-term risk, low short-term/high lifetime risk and low short-term/low lifetime risk were 18.9%, 62.7% and 18.4% respectively. In the COPD category, the corresponding prevalence estimates were calculated as 35.8%, 53.2% and 11.1% respectively. Predicted 30-year risk(SE) of CCVD was estimated as 47.2(0.8)% in the COPD group, which was significantly higher than 37.9(0.5)% in the non-COPD group(p<0.001).

CONCLUSIONS: We observed a significantly increased prevalence of CCVD among subjects with COPD. Among subjects without pre-existent CCVD, the risk of developing CCVD in the future was significantly higher in the COPD group as compared to the non-COPD group.

CLINICAL IMPLICATIONS: Aggressive cardiovascular risk factor modification is imperative towards prevention of development of CCVD among patients with COPD.

DISCLOSURE: The following authors have nothing to disclose: Shikhar Agarwal, Haala Rokadia, Todd Senn

No Product/Research Disclosure Information

Cleveland Clinic, Cleveland, OH

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543